THROMBOCYTHEMIA ESSENTIAL

Clinical trials for THROMBOCYTHEMIA ESSENTIAL explained in plain language.

Never miss a new study

Get alerted when new THROMBOCYTHEMIA ESSENTIAL trials appear

Sign up with your email to follow new studies for THROMBOCYTHEMIA ESSENTIAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

Bomedemstat extension trial tests Long-Term safety for blood cancer patients

Disease control Completed

This study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, sp…

Matched conditions: THROMBOCYTHEMIA ESSENTIAL

Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

THROMBOCYTHEMIA ESSENTIAL

Get alerted when new THROMBOCYTHEMIA ESSENTIAL trials appear

Bomedemstat extension trial tests Long-Term safety for blood cancer patients